ARYMO ER Drug Patent Profile

When do Arymo Er patents expire, and what generic alternatives are available?

Arymo Er is a drug marketed by Zyla and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twelve patent family members in twelve countries.

The generic ingredient in ARYMO ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Arymo Er

A generic version of ARYMO ER was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for ARYMO ER

International Patents:	12
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	8
Patent Applications:	3,941
Drug Prices:	Drug price information for ARYMO ER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARYMO ER
DailyMed Link:	ARYMO ER at DailyMed

See drug prices for ARYMO ER

Paragraph IV (Patent) Challenges for ARYMO ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARYMO ER	Extended-release Tablets	morphine sulfate	15 mg, 30 mg and 60 mg	208603	1	2017-12-29

US Patents and Regulatory Information for ARYMO ER

ARYMO ER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-001	Jan 9, 2017		DISCN	Yes	No			Y
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-002	Jan 9, 2017		DISCN	Yes	No			Y
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-001	Jan 9, 2017		DISCN	Yes	No			Y
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-002	Jan 9, 2017		DISCN	Yes	No			Y
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-003	Jan 9, 2017		DISCN	Yes	No			Y
Zyla	ARYMO ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	208603-003	Jan 9, 2017		DISCN	Yes	No			Y

International Patents for ARYMO ER

See the table below for patents covering ARYMO ER around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013285988	Abuse deterrent pharmaceutical compositions for controlled release
Brazil	112015000150	composições farmacêuticas dissuasoras de abuso de liberação controlada
Canada	2877183	COMPOSITIONS PHARMACEUTIQUES DE DISSUASION D'ABUS A LIBERATION CONTROLEE (ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE)
China	104684548	Abuse deterrent pharmaceutical compositions for controlled release
Eurasian Patent Organization	201590165	СДЕРЖИВАЮЩИЕ ЗЛОУПОТРЕБЛЕНИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ
European Patent Office	2877161	COMPOSITIONS PHARMACEUTIQUES DE DISSUASION D'ABUS À LIBÉRATION CONTRÔLÉE (ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE)

Last updated: July 28, 2026

ARYMO ER market dynamics and financial trajectory (revenue, growth, payer/coverage, and exclusivity-to-generic risk)

ARYMO ER (oral extended-release; active ingredient not provided) shows a market pattern typical of controlled-release, brand-only CNS/pain or cardiometabolic category products: revenue is driven by formulary access and persistence, with profitability constrained by payer step edits and the risk of label erosion if near-term generics or authorized generics enter. A complete financial trajectory and patent-to-generic “when-to-risk” map cannot be produced without the ARYMO ER active ingredient strength, NDA/ANDA identifiers, FDA Orange Book listing, and documented sales baselines.

What is the ARYMO ER market opportunity and where does revenue come from?

Revenue drivers (structural)

• Net sales are primarily determined by (1) formulary placement, (2) prior authorization and step therapy frequency, (3) patient persistence with extended-release regimens, and (4) channel mix (retail vs. specialty/distributor).
• For ER products, average monthly prescription volume and adherence tend to be more stable than immediate-release, but coverage actions can still cause step-down volatility.

Market structure factors

• Payer contracting: ER products in competitive classes often face tighter rebates as newer, safer, or cheaper therapeutics gain share.
• Plan design: Closed formularies or narrow utilization management caps can directly limit addressable volume.
• Competitive substitution: If therapeutic alternatives exist (same MOA, different ER, or IR), switching can compress annual growth.

How does ARYMO ER compete against similar extended-release drugs in its class?

Key competitive dimensions

• Therapeutic equivalence perception: ER brands can lose share if payers view another ER product as clinically interchangeable.
• Coverage hierarchy: Preferred products in a class often get “first dollar” placement; non-preferred brands experience delayed reimbursement.
• Tolerability and adherence claims: In ER segments, payer confidence in adherence and reduced dosing complexity matters for coverage outcomes.

Commercial risk vectors

• Loss of preference status typically produces step-down net sales rather than linear decline.
• Generic entry risk is usually dominated by (1) exclusivity remaining, (2) patent litigation posture, and (3) whether generics can design around key formulation or method-of-use claims.

What are the exclusivity timelines that govern ARYMO ER net sales?

A defensible exclusivity-to-peak-sales model requires:

• NDA number and Orange Book “drug product” mapping
• listed patents (composition, method-of-use, formulation, polymorph, salt, delivery system)
• dates for patent expiration and regulatory exclusivities (NCE, 5-year, pediatric exclusivity, etc.)

Without the ARYMO ER active ingredient and NDA/Orange Book identifiers, a timeline with specific “first generic eligible date” and “risk window for Paragraph IV” cannot be generated.

When does ARYMO ER lose exclusivity and what generic entry risks exist?

A generic entry risk assessment depends on:

• whether any Orange Book patents are “pre-harvest” or listed to the drug product
• whether patents are still enforceable or have been invalidated/expired
• whether there are pending ANDAs with Paragraph IV certifications

Without the Orange Book patent and ANDA litigation record tied to ARYMO ER, any “when-to-launch” conclusion would be non-actionable.

What patents protect ARYMO ER and how strong is the patent estate?

A patent estate strength view normally quantifies:

• number of listed Orange Book patents by category (composition, formulation, method-of-use, manufacturing)
• claim breadth indicators (surrounding formulation windows, excipient/particle specs, release mechanism parameters)
• litigation history (asserted vs. remaining, court outcomes)
• geographic coverage (US only vs. PCT-family expansion in key markets)

No patent dataset for ARYMO ER is provided, so the estate cannot be mapped into a litigation-ready inventory.

What patent litigation affects ARYMO ER and which companies are challenging it?

A litigation impact model requires:

• case captions and court(s)
• asserted patents and infringement theories
• dates: complaint filing, preliminary injunction hearings, trial outcomes, settlement dates
• resulting generic launch timelines via settlement stipulations

No litigation record is included in the prompt, so the section cannot be completed to a standard suitable for licensing, arbitration, or investment decisions.

What is the Orange Book status of ARYMO ER?

A complete Orange Book status summary requires listing:

• NDA holder and label
• dosage forms/strengths mapped to the drug product
• patent numbers, expiration dates, and exclusivity codes (if applicable)
• pediatric exclusivity or other extensions

The prompt does not provide ARYMO ER identifiers needed to extract Orange Book listings.

What formulations are protected by ARYMO ER patents?

For ER products, formulation protection often targets:

• controlled-release polymer matrix or coating systems
• drug-polymer ratios, particle sizes, bead geometry
• osmosis/embedded pellet architectures or multilayer matrices
• specific excipient compositions affecting release profile

A formulation patent map requires the actual patent numbers or claims listing tied to ARYMO ER. Without that, no accurate “what is protected” inventory can be produced.

What method-of-use patents are relevant to ARYMO ER?

Method-of-use and dosing regimen patents typically govern:

• dosing frequency, titration, or combination regimens
• specific patient subpopulations (renal impairment, geriatric, comorbidities)
• clinically defined end points or dosing intervals

No ARYMO ER method-of-use patent list is included, preventing an enforceability analysis.

How does ARYMO ER compare with biosimilars or biologics risks in the market?

If ARYMO ER is a small molecule ER, biosimilar risk is not the primary threat vector. If it is part of an ecosystem with biologic competitors, the comparison is still driven by:

• switching incentives at payers
• value-based contracting
• safety and monitoring burdens

Because the active ingredient is not provided, category placement (small molecule vs. other) cannot be determined, so a biosimilar comparison is not implementable.

How do payer contracting and pharmacy benefit dynamics influence ARYMO ER financial results?

Contracting mechanics likely to move the P&L

• Rebate intensity typically increases when a brand is downgraded to non-preferred tiers.
• PBM formulary placement changes can create abrupt changes in net sales.
• Specialty pharmacy channels are generally less relevant for ER oral small molecules, but distributor incentives can still drive buy-in and persistence.

What to monitor for financial trajectory

• changes in formulary status at top PBMs and national accounts
• increased prior authorization rates
• shifts in average realized price due to rebate modifications
• channel inventory build-ups and sell-through vs. shipment patterns

No ARYMO ER sales disclosure or payer plan metrics are included, so a quantified financial trajectory cannot be constructed.

What is the expected revenue trajectory for ARYMO ER over the next 3–5 years?

A quantified forecast normally ties:

• base growth from volume/persistence
• price erosion drivers (rebate pressure, reference pricing, generic competition)
• exclusivity remaining (patent and regulatory)
• competitive entries (new branded ER, generics, AB-rated substitutes)

The prompt includes no starting revenue, guidance, or category identifiers, so a credible forecast with numeric bands cannot be produced.

What generic launch scenarios could occur for ARYMO ER and how would they impact revenue?

Scenario framework (non-numeric)

• Launch at first eligibility: rapid share loss concentrated in the early months.
• Delayed launch via litigation/settlement: reduced immediate erosion but continued risk as launch approaches.
• Design-around strategy: potential launch with limited label or different dosing constraints, moderating competitive intensity.
• Authorized generic: often compresses peak share loss dynamics by capturing manufacturing-side economics while maintaining supply.

Without Orange Book/patent/litigation facts for ARYMO ER, launch scenario construction cannot be anchored to real dates.

Key Takeaways

• ARYMO ER’s market and financial trajectory in ER segments is driven by formulary access, utilization management, and persistence, with revenue volatility tied to payer tier status changes.
• A patent-to-generic risk map and exclusivity timeline are not producible from the information provided.
• No quantified net sales, growth rates, or forecast horizons can be stated without ARYMO ER’s active ingredient, NDA/Orange Book identifiers, and sales baselines.

FAQs

1. What are the fastest indicators that ARYMO ER is losing formulary coverage?
2. How do settlement terms in ER drug patent cases typically affect generic entry timing?
3. What pricing and rebate levers most strongly influence net sales for extended-release brands?
4. How can a formulation design-around change the competitiveness of an ER generic?
5. What Orange Book patent categories most often delay generic ER competition?

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and related NDA/BLA review information. U.S. Food and Drug Administration.